“The largest barrier to participation in clinical trials is awareness — patients aren’t aware clinical trials exist and don’t know how to get started,” said Ivor Clarke, CEO at SubjectWell. “By building awareness and creating the first true trial marketplace, we provide patients with greater choice and access to innovative treatments. Our investors’ support allows us to reach more interested patients and fill our clients’ studies faster.”
This round of funding will support SubjectWell’s international expansion by helping the company extend its services beyond North America and into Europe, South America, and the United Kingdom.
“Our growth is not just deepening the patient pool,” said Tony Averbeck, vice president of business development at SubjectWell. “Our performance-based pricing model, where we’re only compensated for patients who randomize, is specifically designed to allow every sponsor to bring all of their trials into SubjectWell’s marketplace.”
“Despite all the recent advances in medicine, clinical trials continue to be a major pain point for stakeholders. The vast majority of trials are delayed and many ultimately fail due to poor patient selection,” said Adam Fine, general partner and CEO at Windham. “We have looked deeply at the clinical trial space and concluded that SubjectWell, with hundreds of studies already recruiting through its marketplace, has demonstrated the most effective model for enrolling clinical trials. We are excited to partner with this terrific team.”
About Windham
Windham Venture Partners is a NY-based venture capital firm focused on healthcare, with particular interest in medtech and healthcare IT.
Windham partners with exceptional entrepreneurs and companies that are developing game-changing technologies to serve unmet needs, improve outcomes and help the lives of large numbers of patients. Windham is led by seasoned healthcare industry executives, operators and investors.
